Your browser doesn't support javascript.
loading
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells.
Vicari, Hugo Passos; Coelho-Silva, Juan Luiz; Pereira-Martins, Diego A; Lucena-Araujo, Antônio Roberto; Lima, Keli; Lipreri da Silva, Jean Carlos; Scheucher, Priscila Santos; Koury, Luisa C; de Melo, Raul A; Bittencourt, Rosane; Pagnano, Katia; Nunes, Elenaide; Fagundes, Evandro M; Kerbauy, Fabio; de Figueiredo-Pontes, Lorena Lobo; Costa-Lotufo, Leticia Veras; Rego, Eduardo Magalhães; Traina, Fabiola; Machado-Neto, João Agostinho.
Afiliação
  • Vicari HP; Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
  • Coelho-Silva JL; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
  • Pereira-Martins DA; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
  • Lucena-Araujo AR; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Faculdade de Medicina, Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Lima K; Department of Genetics, Federal University of Pernambuco, Recife, Brazil.
  • Lipreri da Silva JC; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Faculdade de Medicina, Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Scheucher PS; Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
  • Koury LC; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
  • de Melo RA; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
  • Bittencourt R; Department of Internal Medicine, University of Pernambuco and Fundação HEMOPE, Recife, Brazil.
  • Pagnano K; Hematology Division, University Hospital of the Federal University of Rio Grande Do Sul, Porto Alegre, Brazil.
  • Nunes E; University of Campinas/Hemocentro-Unicamp, Campinas, Brazil.
  • Fagundes EM; Hematology Division, Federal University of Paraná, Curitiba, Brazil.
  • Kerbauy F; Hematology Division, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • de Figueiredo-Pontes LL; Hematology Division, Federal University of Sao Paulo, Sao Paulo, Brazil.
  • Costa-Lotufo LV; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
  • Rego EM; Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
  • Traina F; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Faculdade de Medicina, Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Machado-Neto JA; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil. ftraina@fmrp.usp.br.
Invest New Drugs ; 40(2): 438-452, 2022 04.
Article em En | MEDLINE | ID: mdl-34837603
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Promielocítica Aguda Limite: Humans Idioma: En Revista: Invest New Drugs Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Promielocítica Aguda Limite: Humans Idioma: En Revista: Invest New Drugs Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil